Community-Acquired Pneumonia Treatment Guidelines

Introduction to Treatment

The American Thoracic Society recommends combination therapy with amoxicillin/clavulanate (875 mg/125 mg twice daily) plus a macrolide (azithromycin 500 mg on day 1, then 250 mg daily for 4 days), or alternatively, monotherapy with a respiratory fluoroquinolone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily) for a 79-year-old outpatient with pneumonia 1, 2, 3

Patients over 65 years automatically require broader antibiotic coverage due to increased risk for drug-resistant Streptococcus pneumoniae (DRSP) and complications 1, 2
Combination β-lactam/macrolide therapy provides strong coverage against typical bacteria (S. pneumoniae, H. influenzae) and atypical pathogens (Mycoplasma, Chlamydophila, Legionella) 1, 2, 4

The American College of Chest Physicians recommends β-lactam component (amoxicillin/clavulanate 875 mg/125 mg twice daily) plus a macrolide component (azithromycin 500 mg on day 1, then 250 mg daily for days 2-5) for combination therapy 1, 2
Respiratory fluoroquinolones as monotherapy are equally effective and offer the convenience of once-daily dosing, which may improve compliance in elderly patients 1, 2, 3

Treat for a minimum of 5 days and ensure the patient is afebrile for 48-72 hours with no more than one sign of clinical instability before discontinuing therapy 4
Most patients show clinical response within 3-5 days 5, 6

Verify the patient is appropriate for outpatient management by confirming absence of severe features such as respiratory rate >30/minute, systolic blood pressure <90 mm Hg, confusion or altered mental status, oxygen saturation <92% on room air, multilobar infiltrates, or need for mechanical ventilation or vasopressors 1, 3, 7

Elderly patients (≥65 years) have higher mortality risk from pneumococcal pneumonia, even with appropriate treatment, and require assessment for comorbidities such as chronic heart disease, lung disease (COPD), diabetes, renal disease, liver disease, or malignancy 1, 2, 3
Both azithromycin and fluoroquinolones can prolong the QT interval, which is particularly concerning in elderly patients, and should be avoided or used with extreme caution in patients with known QT prolongation or history of torsades de pointes, concurrent use of Class IA or III antiarrhythmics, uncorrected hypokalemia or hypomagnesemia, bradycardia, or heart failure 7, 4

Clinical review at 6 weeks is essential to ensure complete resolution and identify any complications 4
Failure to respond within 3-5 days warrants reassessment for incorrect diagnosis, resistant pathogens, complications, or need for hospitalization 5, 6

Do not use simple amoxicillin monotherapy in a 79-year-old—age alone mandates coverage for atypical pathogens 1, 2
Macrolide monotherapy is inadequate in areas with pneumococcal macrolide resistance >25% (most of the US) and in elderly patients with comorbidities 1, 2
Avoid fluoroquinolone overuse in low-risk patients to prevent resistance, but this 79-year-old qualifies for their use 4
Do not delay treatment while awaiting diagnostic tests; empiric therapy should begin immediately 4